Related Experiment Video
Updated: Feb 27, 2026
10:11
Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
37.1K
Ebola Vaccine: How Far are we?
Rajani Sharma1, Ketki Jangid1, Anuradha2
1Senior Resident, Department of Microbiology, PGIMER and Dr. Ram Manohar Lohia Hospital, New Delhi, India.
Journal of Clinical and Diagnostic Research : JCDR
|June 30, 2017
Summary
Ebola virus causes severe hemorrhagic fever with high mortality. This review examines progress in developing effective Ebola virus vaccines, prioritizing those with commercial potential.
Area of Science:
- Virology
- Epidemiology
- Vaccinology
Background:
- Ebola virus is an emerging infectious disease agent causing severe hemorrhagic fever with high mortality rates (50-90%).
- It poses a significant global health and potential biothreat concern.
- Currently, no licensed vaccines exist for pre- or post-exposure treatment.
Purpose of the Study:
- To review the current progress in the development of Ebola virus vaccines.
- To identify vaccine development strategies with the greatest potential for commercialization.
Main Methods:
- Literature review of recent advancements in Ebola virus vaccine research.
- Analysis of vaccine candidates based on their potential for large-scale production and deployment.
Main Results:
- Several vaccine candidates are in various stages of development.
- Different vaccine platforms (e.g., viral vectors, subunit vaccines) show promise.
- Challenges remain in achieving broad efficacy and long-term immunity.
Conclusions:
- Accelerated development of effective Ebola virus vaccines is crucial.
- Focusing on strategies with commercial viability is key to ensuring global access.
- Continued research and international collaboration are essential for combating Ebola outbreaks.
